CRS: House Drug Bill’s Excise Tax Could Face Constitutional Challenge

By Rachel Cohrs / October 25, 2019 at 6:11 PM
Provisions of House Democrats’ government drug price negotiation bill could be vulnerable to constitutional challenges, according to an Oct. 21 memo by the nonpartisan Congressional Research Service. The excise tax in H.R. 3 is particularly vulnerable because it’s so harsh that the high court could consider it too excessive, CRS lawyers warn, but Democrats are not worried about constitutional challenges because Congress has broad authority over taxes. “The excise tax this bill would impose on drug manufacturers that continue to...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.